A Trial of GFH018 in Combination With Toripalimab and Concurrent Chemoradiotherapy in Stage III NSCLC
Status:
Not yet recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This is a phase II trial assessing the efficacy and safety of GFH018 in combination with
Toripalimab given concurrently with platinum-based chemoradiotherapy (CRT) in patients with
unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC).